Upon joining the study, the patient will provide informed consent, confirming understanding of the study’s purpose and procedures.

The patient will undergo initial assessments to confirm eligibility, including a review of medical history and current health status.

The patient will receive a combination of zolbetuximab, nab-paclitaxel, and gemcitabine to determine the recommended dose.

Zolbetuximab is administered intravenously as a solution prepared from a powder.

The patient’s response to the medication will be monitored closely to assess safety and tolerability.

The patient will be randomly assigned to receive either the combination of zolbetuximab, nab-paclitaxel, and gemcitabine or nab-paclitaxel and gemcitabine alone.

The goal is to evaluate if the addition of zolbetuximab improves overall survival compared to the standard treatment.

The patient will receive the assigned treatment regimen on a regular schedule, typically involving cycles of administration followed by rest periods.

The specific dosage and frequency will be determined by the study protocol and the patient’s response to treatment.

Throughout the study, the patient will undergo regular assessments to monitor health status, including blood tests, imaging studies, and physical examinations.

These assessments will help evaluate the effectiveness of the treatment and any potential side effects.

Upon completion of the treatment phase, the patient will undergo final assessments to determine the overall impact of the treatment.

The patient will be informed of the study’s findings and any further steps, if applicable.